Gabapentin Capsule
Product Images NDC 71335-1348

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A text panel displaying a formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. The formula is intended for clinical reference but does not provide dosing or specific drug information.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to an aminomethyl group (CH2NH2) and an acetic acid group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for Gabapentin than for placebo.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline to week 7, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores decreasing over time, with Gabapentin groups showing greater reduction compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates in two studies. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin (GBP) 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels are noted with asterisks above bars.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A chart showing the percentage difference on the y-axis plotted against daily dose in milligrams on the x-axis. The chart includes data points from three studies labeled "a," "b," and "c," with markers in black, gray, and white respectively, demonstrating differences at doses of 600 mg, 900 mg, 1200 mg, and 1800 mg.*

FDA Label Image

Lbl7133513482

Label for Gabapentin 300 mg capsule by Bryant Ranch Prepack, packaged in Burbank, CA. The label indicates a yellow/brown capsule, with a quantity of 30 capsules. It includes storage instructions at room temperature (20°-25°C), a warning for dizziness, and a barcode. The label also references Neurontin 300 mg capsules for comparison and shows the NDC 71335-1348.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.